Editas Medicine Presents EDIT-401 Data Showing Over 90% Mean LDL-C Reduction in Nonhuman Primates

• Editas Medicine reported greater than 90% mean LDL-C reduction with a single EDIT-401 dose in nonhuman primates, sustained through approximately 10 months.
• Preclinical safety findings showed transient liver enzyme elevations, with no bilirubin elevations or liver histopathological changes.
• Initial safety and tolerability data from the Strive study are expected in the first quarter of 2027.
• Part 1 enrollment completion and topline safety and efficacy results are targeted for the second half of 2027.
• Cash runway extends into the second half of 2028.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Editas Medicine Inc. published the original content used to generate this news brief on November 10, 2026, and is solely responsible for the information contained therein.